Preoperative neoadjuvant chemotherapy in patients with breast cancer evaluated using strain ultrasonic elastography

Table 1 Comparison of strain ratio and elasticity scores between pathological complete remission and non-pathological complete remission patients

Groups	Cases	SR	Elasticity score 4-5, n (%)
pCR	20	5.50 ± 1.16	3 (15.00)
Non-pCR	70	12.29 ± 6.60	54 (77.14)
t/χ2 value		-4.563	25.868
P value		0.000	0.000

pCR: Pathological complete remission; SR: Strain ratio.

Table 2 Comparison of general clinical data of patients with different flexibility scores, n (%)

Groups	Elasticity score 4-5	Elasticity score 1-3	t value	P value
Cases	57	33
Age (yr)	50.06 ± 8.02	50.82 ± 9.11	-0.412	0.681
ER positive	35 (61.40)	18 (54.55)	0.406	0.524
PR positive	30 (52.63)	16 (48.48)	0.144	0.705
Ki-67 > 14%	32 (56.14)	19 (57.58)	0.018	0.895
HER2 positive	14 (24.56)	5 (15.15)	1.111	0.292
Lesion diameter (cm)	4.35 ± 1.13	4.30 ± 1.10	0.204	0.839

ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epidermal growth factor receptor 2.

Table 3 Comparison of SR among patients with different elasticity scores

Group	Cases	SR	t value	P value
Elasticity score 4-5	57	11.28 ± 1.43	4.271	0.000
Elasticity score 1-3	33	9.92 ± 1.50

SR: Strain ratio.

Table 4 Comparison of general clinical data of pathological complete remission and non-pathological complete remission patients, n (%)

General clinical data	pCR	Non-pCR	t/χ2 value	P value
Cases	20	70
Age (yr)	49.02 ± 8.19	51.02 ± 9.92	-0.824	0.412
Lesion diameter (cm)	4.42 ± 1.23	4.12 ± 1.20	0.981	0.329
ER positive	12 (60.00)	41 (58.57)	0.013	0.909
PR positive	11 (55.00)	35 (50.00)	0.156	0.693
Ki-67 > 14%	17 (85.00)	34 (48.57)	8.407	0.004
HER2 positive	7 (35.00)	12 (17.14)	2.003	0.157
Pathological type			0.386	0.534
Invasive ductal carcinoma	16 (80.00)	62 (88.57)
Invasive lobular carcinoma	4 (20.00)	8 (11.43)
Molecular subtypes			2.548	0.467
Triple negative	3 (15.00)	10 (14.29)
HER2	6 (30.00)	23 (32.86)
Luminal B	11 (55.00)	30 (42.86)
Luminal A	0 (0.00)	7 (10.00)

pCR: Pathological complete remission; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epidermal growth factor receptor 2.

Table 5 Correlation coefficient

Index	SR
	rs value	P value
Age	0.193	0.304
Lesion diameter	0.182	0.353
ER positive	0.082	0.405
PR positive	0.100	0.722
Ki-67 > 14%	0.092	0.565
HER2 positive	0.182	0.672
Elasticity score	0.411	0.000

SR: Strain ratio; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epidermal growth factor receptor 2.

Table 6 Logistic regression analysis

Factor	β	SE	Walds	P value	OR (95%CI)
Ki-67 > 14%	-0.440	0.132	11.111	0.000	0.644 (0.497-0.834)
SR	0.355	0.122	8.467	0.000	1.426 (1.123-1.811)
Elasticity score 4-5	0.312	0.2112	7.760	0.000	1.366 (1.097-1.702)

SR: Strain ratio.

Table 7 Receiver operator characteristic curve parameters

Index	Area under curve	P value	Sensitivity	Specificity
SR	0.802	0.000	80.00%	70.00%
SR combined flexibility score	0.891	0.000	82.00%	83.00%

SR: Strain ratio.